Syda Productions / Shutterstock.com
The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.
The pharmaceutical industry is becoming increasingly interested in digital health and serious money is being invested in the technology.
For example, Roche has invested in mySugr, a company that offers an app to help patients manage their diabetes, and Propeller Health is a company working on connected inhaler technology with GSK, Aptar and Boehringer Ingelheim.
Pharmaceutical companies are used to an established commercial formula for bringing new products to market, with product development involving a significant up-front investment including research and development costs and generating the requisite quality, safety and efficacy data.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Hogan Lovells, RGC Jenkins, Stephen Bennett, Elisabethann Wright, Mark Marfe, trademark, digital age, European Commission, patent, MA,